Given its high levels in invasive BCC and its ability to overcome WIRE deficiency, we propose WIP as a potential therapeutic target for treatment of metastatic cancer and as a prognostic marker for breast cancer patients. This evidence concerns the gene WIPF2 and skin basal cell carcinoma.